Supplemental
. Schematic illustration of the CellKey assay protocol employed in the present study. (A) The protocol employed (see also "Materials and Methods" for details): human AT 1 Roverexpressing HEK293 cells were incubated with the agent of interest for 40 min at room temperature (Stimulation I) and the change in impedance (ΔZ iec ) was recorded to derive efficacy of AT 1 R activation (EC 50ac ). To measure degree of inhibition of AngII-induced signaling ("efficacy of AT 1 R desensitization"), the change in impedance (ΔZ iec ) upon a second challenge with 5 nM AngII for 10 min (Stimulation II, Agonist: AngII), immediately following agent washout from the previous treatment, was recorded and the EC 50des for each agent was derived. (B) Representative dose-response impedance recordings upon Stimulation I for each drug/agent to measure efficacy at AT 1 R activation. (C) Representative dose-response impedance recordings upon Stimulation II for each drug/agent to measure efficacy at inhibiting 5 nM AngII-activated AT 1 R signaling. Los: Losartan; EXP: EXP3174; Tel: Telmisartan; Epr: Eprosartan; Azi: Azilsartan; Olm: Olmesartan; Can: Candesartan; Val: Valsartan; Irb: Irbesartan.
